scholarly journals Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England

2020 ◽  
Vol 10 ◽  
pp. 204512532095461
Author(s):  
Vicki Osborne ◽  
Miranda Davies ◽  
Alison Evans ◽  
Saad A. W. Shakir
Keyword(s):  
Secondary Care ◽  
Care Setting ◽  
Bipolar Affective Disorder ◽  
Immediate Release ◽  
Observational Assessment ◽  
Event Monitoring ◽  
Observational Cohort ◽  
Secondary Care Setting ◽  
Cohort Event Monitoring ◽  
Final Cohort

Background: This study was designed to monitor the short-term (up to 12 weeks) use and safety of quetiapine (Seroquel) extended release (XL) and quetiapine immediate release (IR) prescribed to patients with a clinical diagnosis of schizophrenia, and/or manic episodes associated with bipolar disorder by psychiatrists under normal conditions of use. Methods: A Specialist Cohort Event Monitoring (SCEM) study was conducted in England February 2010–April 2013. This observational cohort study recruited patients prescribed quetiapine XL within the secondary care setting by psychiatrists. A reference cohort of quetiapine IR users was also recruited. Baseline and 12 week observational data were collected from psychiatrists who abstracted information from medical records onto bespoke questionnaires. Data were collected on demographics, indication, past medical history, prescribing information and events of interest. Summary descriptive statistics were calculated. Results: The final cohort consisted of 869 eligible patients; 646 XL users and 223 IR users. The majority of XL and IR users were female (56.2% and 55.6%, respectively), with a median age of 40 (interquartile range [IQR]: 29, 49) and 39 (IQR: 28, 50) years, respectively. The most frequent indication for treatment was Manic episodes associated with Bipolar Affective disorder (53.4% XL and 49.8% IR). Median index dose was 200 mg/day (IQR: 100, 300) for XL users and 50 mg/day (IQR: 50, 100) for IR users, while median final maintenance dose was 400mg/day (IQR: 250, 600) and 300 mg/day (IQR: 100, 400), respectively. The most frequently reported event of interest in both cohorts was sedation ( n = 151, 23.9% XL cohort and n = 49, 23.0% IR cohort). Conclusion: Utilisation of quetiapine XL appeared to be in line with prescribing guidelines in terms of dose, and commonly reported events of interest were in concordance with the known safety profile. Overall, this SCEM study provided important information on the safety and utilisation of quetiapine XL in the secondary care setting in England.

AACE2021-A-1090: Health Status, of Medical and Allied Health Staff of a Secondary Care Setting in a Developing Country

2021 ◽  
Vol 27 (12) ◽  
pp. S23-S24
Author(s):  
Maryam Batool ◽  
Beenish Khan ◽  
Muhammad Zaka-Ul Haq ◽  
Muhammad Raza-Ul Haq
Keyword(s):  
Health Status ◽  
Developing Country ◽  
Secondary Care ◽  
Allied Health ◽  
Care Setting ◽  
Health Staff ◽  
Secondary Care Setting

Etiology and diagnosis of ascites: contemporary cohort study in a secondary care setting

2020 ◽  
Vol 73 ◽  
pp. S764
Author(s):  
Mohsan Subhani ◽  
Peuish Sugathan ◽  
Guruprasad Aithal ◽  
Emilie Wilkes ◽  
Naaventhan Palaniyappan
Keyword(s):  
Cohort Study ◽  
Secondary Care ◽  
Care Setting ◽  
Secondary Care Setting

scholarly journals Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a cohort study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Rajkumar Chinnadurai ◽  
Onesi Ogedengbe ◽  
Priya Agarwal ◽  
Sally Money-Coomes ◽  
Ahmad Z. Abdurrahman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Secondary Care ◽  
Clinical Characteristics ◽  
Care Setting ◽  
Older Age ◽  
Medical Unit ◽  
Acute Medical Unit ◽  
Secondary Care Setting ◽  
Group 2 ◽  
Group 1

Abstract Background There is a need for more observational studies across different clinical settings to better understand the epidemiology of the novel COVID-19 infection. Evidence on clinical characteristics of COVID-19 infection is scarce in secondary care settings in Western populations. Methods We describe the clinical characteristics of all consecutive COVID-19 positive patients (n = 215) admitted to the acute medical unit at Fairfield General Hospital (secondary care setting) between 23 March 2020 and 30 April 2020 based on the outcome at discharge (group 1: alive or group 2: deceased). We investigated the risk factors that were associated with mortality using binary logistic regression analysis. Kaplan-Meir (KM) curves were generated by following the outcome in all patients until 12 May 2020. Results The median age of our cohort was 74 years with a predominance of Caucasians (87.4%) and males (62%). Of the 215 patients, 86 (40%) died. A higher proportion of patients who died were frail (group 2: 63 vs group 1: 37%, p < 0.001), with a higher prevalence of cardiovascular disease (group 2: 58 vs group 1: 33%, p < 0.001) and respiratory diseases (group 2: 38 vs group 1: 25%, p = 0.03). In the multivariate logistic regression models, older age (odds ratio (OR) 1.03; p = 0.03), frailty (OR 5.1; p < 0.001) and lower estimated glomerular filtration rate (eGFR) on admission (OR 0.98; p = 0.01) were significant predictors of inpatient mortality. KM curves showed a significantly shorter survival time in the frail older patients. Conclusion Older age and frailty are chief risk factors associated with mortality in COVID-19 patients hospitalised to an acute medical unit at secondary care level. A holistic approach by incorporating these factors is warranted in the management of patients with COVID-19 infection.

FRI-049-Real world experience of obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis in the secondary care setting

2019 ◽  
Vol 70 (1) ◽  
pp. e405-e406
Author(s):  
Anthony Pratt ◽  
Lucy Turner ◽  
John Hutchinson ◽  
Laura Maher ◽  
Dawn Orange ◽  
...  
Keyword(s):  
Real World ◽  
Secondary Care ◽  
Care Setting ◽  
Primary Biliary Cholangitis ◽  
Obeticholic Acid ◽  
Secondary Care Setting
Sign in / Sign up

Export Citation Format

Share Document